Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2154
Journal of Biotechnology & Biomaterials received 2154 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- ResearchBible
- China National Knowledge Infrastructure (CNKI)
- Access to Global Online Research in Agriculture (AGORA)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Analytical next-generation sequencing approaches for CRISPR-Cas9-mediated cell engineering
Joint Event on 24th Biotechnology Congress: Research & Innovations & Annual Congress on CRISPR Cas9 Technology and Genetic Engineering
Haythem Latif
GENEWIZ, USA
ScientificTracks Abstracts: J Biotechnol Biomater
Abstract
CRISPR-Cas9-mediated cell lines hold great promise to transform therapeutics in various disease areas. Next-generation sequencing (NGS) is a powerful analytical tool with applications designed throughout the CRISPR-Cas9 workflow from discovery, through screening, and to validation of CRISPR-Cas9 effects. Here we will review contemporary workflows for CRISPR-Cas9 knockout libraries and briefly highlight how NGS and advanced informatics facilitates drug target identification. We will also detail various routes for optimizing and screening CRISPR-Cas9 pools and isolates for on- and off-target activity. Moving beyond screening and lead identification, we will review novel unguided NGS approaches to demonstrate on-target specificity while confirming low/no off-target activity prior to clinical trials.Biography
Haythem Latif is a life science professional with a passion for next-generation sequencing technologies and applications. His interests in NGS began during his time as a graduate student pursing a PhD in Bioengineering from the University of California, San Diego. There, he generated, analyzed, and integrated multi-omic datasets to deeply characterize the genome organization of various microbial organisms in search of novel biological insights. Upon graduation, he worked for ThermoFisher in the Ion Torrent applications team focusing on AmpliSeq panel development. He is currently managing NGS Business & Strategic Partnerships at GENEWIZ.
E-mail: haythem.latif@genewiz.com
